304 related articles for article (PubMed ID: 22734475)
1. Long-term potency preservation following brachytherapy for prostate cancer.
Snyder KM; Stock RG; Buckstein M; Stone NN
BJU Int; 2012 Jul; 110(2):221-5. PubMed ID: 22734475
[TBL] [Abstract][Full Text] [Related]
2. Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma.
Buckstein M; Kerns S; Forysthe K; Stone NN; Stock RG
BJU Int; 2013 Mar; 111(3 Pt B):E43-7. PubMed ID: 23046084
[TBL] [Abstract][Full Text] [Related]
3. Erectile function after permanent prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Stipetich RL; Abel LJ; Lief JH
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):893-902. PubMed ID: 11958881
[TBL] [Abstract][Full Text] [Related]
4. Erectile function durability following permanent prostate brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Kurko BS; Anderson R; Lief JH
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):639-48. PubMed ID: 19303721
[TBL] [Abstract][Full Text] [Related]
5. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer.
Stock RG; Kao J; Stone NN
J Urol; 2001 Feb; 165(2):436-9. PubMed ID: 11176391
[TBL] [Abstract][Full Text] [Related]
6. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
7. Erectile function after brachytherapy with external beam radiation for prostate cancer.
Fujioka H; Ishimura T; Sakai Y; Fujii T; Jo Y; Takenaka A; Fujisawa M
Arch Androl; 2004; 50(4):295-301. PubMed ID: 15277008
[TBL] [Abstract][Full Text] [Related]
8. Impact of race on biochemical disease recurrence after prostate brachytherapy.
Yamoah K; Stone N; Stock R
Cancer; 2011 Dec; 117(24):5589-600. PubMed ID: 21692058
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.
Teloken PE; Ohebshalom M; Mohideen N; Mulhall JP
J Urol; 2007 Dec; 178(6):2521-5. PubMed ID: 17937948
[TBL] [Abstract][Full Text] [Related]
10. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
11. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
[TBL] [Abstract][Full Text] [Related]
12. Erectile function after prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL; Kurko BS; Lief JH; Allen ZA
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):437-47. PubMed ID: 15890585
[TBL] [Abstract][Full Text] [Related]
13. Five-year potency preservation after iodine-125 prostate brachytherapy.
Nishimura S; Yorozu A; Ohashi T; Sakayori M; Yagi Y; Nishiyama T; Saito S; Shiraishi Y; Yoshida K; Toya K; Shigematsu N
Int J Clin Oncol; 2014 Oct; 19(5):940-5. PubMed ID: 24170247
[TBL] [Abstract][Full Text] [Related]
14. Predictors of metastatic disease after prostate brachytherapy.
Forsythe K; Burri R; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):645-52. PubMed ID: 22137025
[TBL] [Abstract][Full Text] [Related]
15. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
16. Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients.
Shiraishi Y; Yorozu A; Ohashi T; Toya K; Seki S; Yoshida K; Kaneda T; Saito S; Nishiyama T; Hanada T; Shigematsu N
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e127-33. PubMed ID: 21398047
[TBL] [Abstract][Full Text] [Related]
17. Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS.
Zagar TM; Stock RG; Cesaretti JA; Stone NN
Brachytherapy; 2007; 6(1):26-33. PubMed ID: 17284382
[TBL] [Abstract][Full Text] [Related]
18. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer.
Kollmeier MA; Pei X; Algur E; Yamada Y; Cox BW; Cohen GN; Zaider M; Zelefsky MJ
Brachytherapy; 2012; 11(4):271-6. PubMed ID: 22192495
[TBL] [Abstract][Full Text] [Related]
20. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]